Latest Ratings for ABNB Date Firm Action From To Mar 2022 Deutsche Bank Initiates Coverage On Hold Mar 2022 Tigress Financial Maintains Buy Feb 2022 Citigroup Maintains Neutral View More Analyst Ratings for ABNB View the Latest Analyst Ratings read more ​ ​Latest Ratings for ABNB DateFirmActionFromTo Mar 2022Deutsche BankInitiates Coverage OnHold Mar 2022Tigress FinancialMaintainsBuy
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including reports of deaths and hospitalizations, while working with the FDA to resolve issues. read more ​ ​Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including reports of deaths and hospitalizations, while working with the
Aurora’s international medical cannabis business bolstered its results, with European sales doubling quarter-over-quarter. read more ​ ​Aurora’s international medical cannabis business bolstered its results, with European sales doubling quarter-over-quarter. read moreÂ
Under Armour reported better-than-expected Q2 2025 results, with revenue declining 10.7% and adjusted EPS of $0.30. The company raised its full-year outlook, leading to a jump in its stock price. read more ​ ​Under Armour reported better-than-expected Q2 2025 results, with revenue declining 10.7% and adjusted EPS of $0.30. The company raised its full-year outlook,
EPAM Systems reported Q3 sales of $1.17 billion, beating analyst estimate of $1.15B. Adjusted EPS of $3.12 also beat consensus of $2.70. read more ​ ​EPAM Systems reported Q3 sales of $1.17 billion, beating analyst estimate of $1.15B. Adjusted EPS of $3.12 also beat consensus of $2.70. read moreÂ
This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.